The TNF-related apoptosis-inducing ligand (TRAIL) is currently under evaluation as a possible (co-)therapeutic in cancer treatment. We therefore examined 129 cell samples from patients with de novo acute leukemia as to their constitutive susceptibility to TRAIL-induced apoptosis in vitro. 
Introduction
Activation of apoptotic signalling pathways plays an important role in chemotherapeutic-induced cell death of tumor cells. [1] [2] [3] TRAIL, a member of the TNF family, was initially shown to induce surface receptor-mediated apoptosis in tumor cells but not in normal cells. 4, 5 In several mouse models, in vivo administration of TRAIL induced apoptosis in a variety of human malignant cells. [6] [7] [8] [9] Several chemotherapeutic agents induced and enhanced TRAIL susceptibility in tumor cells in vitro and in vivo. [9] [10] [11] Therefore, TRAIL may have potential as a cancer (co-)therapeutic in human malignancies. However, in light of recently published studies, the in vivo application of TRAIL might be associated with severe liver damage and cell death of normal brain cells in humans. 12, 13 TRAIL also induced apoptosis in erythroblasts within normal hematopo- 14 Thus, the use of TRAIL in human cancer therapy must be considered with caution and further investigations should be included in the preclinical evaluation of TRAIL. 12, 13 TRAIL can bind to at least four different cell surface receptors: TRAIL-R1 (also called DR4) and TRAIL-R2 (also called KILLER/DR5) are receptors with two cysteine-rich extracellular ligand-binding domains and a cytoplasmic death domain that signals downstream caspase activation. TRAIL-R3 (also called DcR1 or TRID) and TRAIL-R4 (also called DcR2 or TRUNDD) are GPI-anchored surface receptors lacking a functional active intracellular death domain. These two receptors are thought to protect cells from TRAIL-mediated apoptosis as decoy receptors by competing with the functionally active TRAIL receptors R1 and R2 for binding to TRAIL. TRAIL receptor gene expression is at least partially controlled in a p53-dependent manner. 4, 5, 15 In human glioma cells, the cytotoxic drug etoposide increased TRAIL-R2 expression, leading to TRAILinduced apoptosis in these tumor cells. 8 Expression levels of TRAIL-R1 and R2 were also upregulated by etoposide treatment in four different epithelial cell-derived tumor cell lines. Inactivation of the transcription factor NF-B blocked the etoposide-induced upregulation of R1 and R2 in these cells. 16 So far, no comprehensive study has investigated comparatively TRAIL sensitivity in different acute leukemia subtypes. In precursor B cell ALL, a rather low TRAIL sensitivity was observed. 17 In this study, exogenous soluble CD40L failed to rescue TRAIL-sensitive leukemic cells from TRAIL-induced apoptosis. 17 TRAIL susceptibility was independent of MDR ('multi-drug resistance') protein overexpression and expression levels of the apoptosis-regulating molecules Bcl-2 and Bax. 18 TRAIL effectively induced apoptosis in multiple myeloma cell lines independently of their Bcl-2 expression levels and was not cytotoxic to CD34 + /CD45 dim hematopoietic stem cells. 19, 20 Primary tumor cells of hematopoietic origin constitutively expressed TRAIL and were able to induce TRAIL-mediated apoptosis in Jurkat cells. 21 The human promyelocytic HL60 cell line showed a constitutive sensitivity to TRAIL-mediated apoptosis, which was downregulated during granulocytic differentiation induced by DMSO. 22 Recent studies also indicated a major role of TRAIL in the regulation of immune processes. [23] [24] [25] [26] Therefore, the functional TRAIL expression of leukemic cells may be involved in tumor cell evasion from immunosurveillance. 21 Inactivation of NF-B led to an increase in TRAIL susceptibility of leukemia cell lines as well as primary acute leukemia cell samples. 27 Pretreatment of leukemic cell lines with chemotherapeutic drugs increased the sensitivity to TRAIL-induced apoptosis of the leukemic cells possibly due to an upregulation of TRAIL-R2. 28 To evaluate TRAIL susceptibility in a larger series of cell samples of patients with de novo acute leukemia, we examined 54 AML, 41 precursor B cell ALL and 34 precursor T cell ALL samples for their in vitro susceptibility to TRAIL-induced apoptosis. To determine whether the expression of the TRAIL receptors R1-R4 and NF-B activation status correlate with Leukemia TRAIL susceptibility, 58 cell samples were examined for R1-R4 expression by RT-PCR, and 39 cell samples for constitutive NF-B activation status by electrophoretic mobility shift assay (EMSA). Finally, we investigated on 49 cell samples, whether the chemotherapeutic agent doxorubicin either sensitized TRAIL-resistant leukemic cells to TRAIL-induced apoptosis or enhanced TRAIL susceptibility in TRAIL-sensitive cell samples in vitro.
Materials and methods

Patients and cell samples
We either examined freshly obtained (n = 107) or prior cryopreserved (n = 22) cell samples from patients with either AML (n = 54; 13 children, 41 adults), or ALL (n = 79; 75 children, four adults/41 precursor B cell ALL, 34 precursor T cell ALL) at initial diagnosis. Diagnosis of AML and ALL was made morphologically according to the revised FAB criteria 29 and immunologically according to the EGIL recommendations. 30, 31 Precursor B cell ALL cases were subclassified into pro-B-ALL, common-ALL, pre-B-ALL, and mature B-ALL, and precursor T cell ALL cases into pro-/pre-T-ALL, cortical T-ALL, and mature T-ALL according to the EGIL guidelines for the immunophenotypic classification of acute leukemias. 30, 31 Samples contained more than 80% leukemic cells based on morphological and immunophenotypic criteria. No significant differences between freshly obtained and prior cryopreserved cell samples were seen for the investigated parameters.
As a positive control for TRAIL susceptibility analysis, we used the TRAIL sensitive T lymphoblastic leukemia cell line Jurkat. 5 For TRAIL receptor R1-R4 mRNA expression analysis by RT-PCR, the cell lines SW620, Jurkat and HL-60 were used as positive controls. 5 
Immunophenotyping
Leukemic cells from heparinized fresh bone marrow or peripheral blood samples were isolated by Ficoll-Hypaque (Pharmacia, Biotech, Freiburg, Germany) density gradient centrifugation, and leukemia-associated cell surface antigens were detected by a panel of moabs either by a direct or indirect immunofluorescence assay as previously described. 32, 33 Cell samples were analyzed by flow cytometry (FACScan; Becton Dickinson, San Diego, CA, USA) using the Cell-Quest-software program (Becton Dickinson). Cell samples were considered positive for a specific antigen, if the antigen was expressed on at least 20% of the leukemic cells ('20-cut-off-level').
31-33
Cell culture and apoptosis assays
To assess spontaneous apoptosis in vitro, 2.5 × 10 5 cells/well were cultured at 37°C in 96-well microtiter plates (Nunc, Roskilde, Denmark) in RPMI 1640 (Biochrom, Berlin, Germany) standard medium containing 10% fetal calf serum, 2 mM Lglutamine, 100 U/ml penicillin, and 100 g/ml streptomycin (Gibco BRL, Paisley, UK) as previously described. 34, 35 To investigate TRAIL-mediated effects, leukemic cells were coincubated with 1 g/ml of soluble, recombinant, human TRAIL (N-terminally tagged with the FLAG epitope; Alexis, San Diego, CA, USA) and trimerized with a FLAG-specific antibody (2 g/ml; Alexis) as described elsewhere. 13 To assess a possible sensitization to TRAIL-induced apoptosis of leukemic cells by the chemotherapeutic agent doxorubicin (Pharmacia & Upjohn, Erlangen, Germany), cells were coincubated with doxorubicin at different concentrations (0.5, 2.5 and 12.5 g/ml) as well as with both TRAIL and doxorubicin, following the above described procedure. All tests were performed in doublets.
To determine the extent of spontaneous, TRAIL-as well as doxorubicin-induced apoptosis after 20-24 h culture, cells were stained with FITC-conjugated annexinV and propidium iodide (PI; 0.3 g/ml; Sigma, Deisenhofen, Germany) using the annexin V-kit (Beckman Coulter, Marseille, France) as described before. 35, 36 Thereafter, samples were analyzed by flow cytometry for the presence of viable (annexin V −ve , PI The extent of cell death was quantified as percentage of annexinV +ve cells, thus detecting both caspase-mediated apoptotic cell death as well as a possible distinct caspaseindependent mode of cell death. 37 Specific TRAIL-induced cell death was assumed, if the percentage of annexinV +ve cells/sample in the presence of TRAIL was at least 10% higher compared to the percentage of annexin V +ve cells/sample in the medium control.
Expression of GAPDH and TRAIL receptors R1-R4 by semi-quantitative RT-PCR
Total RNA was isolated from the cell samples using the Invisorb RNA Kit II (InViTek, Berlin, Germany) according to the manufacturer's instructions. Afterwards, cDNA synthesis was performed using the Reverse Transcription System (Promega, Mannheim, Germany) with the supplied oligo(dT) 15 primer. RT was performed using a thermal program of 42°C for 30 min. and 94°C for 5 min. For PCR reactions the following primers were used: GAPDH (fwd: 5Ј-CAT CAG CAA TGC CTC CTG CAC C-3Ј; rev: 5Ј-GTT GAA GTC AGA GGA GAC CAC C-3Ј), TRAIL-R1 (fwd: 5Ј-CTG AGC AAC GCA GAC TCG CTG TCC AC-3Ј; rev: 5Ј-TCC AAG GAC ACG GCA GAG CCT GTG CCA T-3Ј), TRAIL-R2 (fwd: 5Ј-GCC TCA TGG ACA ATG AGA TAA AGG TGG CT-3Ј; rev: 5Ј-CAA ACC AAA TCT CAA AGT ACG CAC AAA CGG-3Ј), TRAIL-R3 (fwd: 5Ј-CAA CAG AGG CAC AGC TTC AAG-3Ј; rev: 5Ј-CTA TGA TCC CTA CGA TGG TGC-3Ј), and TRAIL-R4 (fwd: 5Ј-GGT CAA GGT CAG TAA TTG TAC G-3Ј; rev: 5Ј-CCA CCA GTT GTT CCT GAA TTG-3Ј) giving products of 424, 506, 502, 622 and 605 bp, respectively. Taq polymerase and PCR reagents were supplied by InViTek. GAPDH PCR cycle conditions were 94°C for 30 s, 58°C for 45 s, and 72°C for 1 min for 36 cycles. For TRAIL-R1, -R2 and -R4 cycle conditions were 94°C for 30 s, 58°C for 45 s, and 72°C for 1 min for 40 cycles. TRAIL-R3 cycle conditions were 94°C for 30 s, 61°C for 45 s, and 72°C for 1 min for 40 cycles. RT and PCR reactions were performed using the omnigene cycler (Hybaid, Heidelberg, Germany). Samples were resolved on a 1.5% agarose gel and visualized with ethidium bromide using the EagleeyeII optical system (Stratagene, La Jolla, CA, USA). Gel band intensities were measured (mean density value) with the Adobe Photoshop (Version 4.0) software program according to the NIH image program guidelines (developed at the US National Institutes of Health and available on the Internet at http://rsb.info.nih.gov/nih-image). TRAIL receptor gene expression of each cell sample examined was standardized to the internal GAPDH control (ratio: (mean density value of the specific TRAIL receptor gel band − mean density of the nonspecific background)/(mean density value of the GAPDH gel band − mean density of the nonspecific background)). Based on these relative expression levels, we grouped the examined cases into three groups: (1) no expression, (2) weak expression (ratio between 0 and 1), and (3) strong expression (ratio Ͼ1) of TRAIL receptors R1 to R4, respectively. All RT-PCR tests were performed at least in doublets for each cell sample examined and results were calculated as mean values of these tests.
NF-B activation status by electrophoretic mobility shift assay (EMSA)
Preparation of whole cell extracts and EMSA conditions were described previously. 38 NF-B DNA binding activity was determined using 32 P-labelled H 2 K probe and Oct-1 DNA binding activity was assayed with the 32 P-labelled Oct-1 probe from the H 2 B promoter.
Statistical analysis
Differences in the relative mRNA expression levels of TRAIL receptors R1-R4 between the leukemia subtypes, TRAIL-sensitive and TRAIL-resistant cell samples and cell samples with high and low NF-B shift activity as well as differences in the TRAIL susceptibility and NF-B shift activity between the leukemia subtypes were evaluated using chi-square test (Pearson coefficient). All statistical analyses were done with the SPSS software program (Version 9.0).
Results
Constitutive TRAIL susceptibility in cell samples of patients with acute leukemia
One hundred and twenty-nine cell samples were examined for their constitutive TRAIL susceptibility in vitro as described in Materials and methods. TRAIL susceptibility ranged from 0% to 42% TRAIL-sensitive cells/sample (Figure 1) . However, only 21 (16%) of the 129 cell samples examined disclosed у10% TRAIL-sensitive cells/sample. Precursor B cell ALL samples were significantly more often TRAIL-sensitive when compared with AML (P Ͻ 0.05) but not with precursor T cell ALL (P = 0.20) using this '10%-cut-off-level' (Figure 1 ). There was no significant correlation between TRAIL susceptibility and immunophenotypic subtypes in ALL as well as maturation stage in AML, and TRAIL sensitivity did not significantly differ between cell samples of children and adults, both in AML and ALL (data not shown). Figure 2 shows a representative example for flow cytometric detection of TRAIL-induced apoptosis in acute leukemia cell sample.
TRAIL receptor R1-R4 mRNA expression and correlation with TRAIL susceptibility in individual cell samples
Fifty-eight cell samples with different levels of TRAIL susceptibility were arbitrarily chosen for TRAIL receptor mRNA expression analysis by semi-quantitative RT-PCR as described
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Figure 1
TRAIL susceptibility of acute leukemia cells (flow cytometric detection of TRAIL-susceptible cells as described in Materials and methods).
in Materials and methods. Fifty-seven cell samples (20 AML, 27 precursor B cell ALL, 10 precursor T cell ALL) were analyzed for their constitutive mRNA expression levels of the TRAIL receptors R1-R4. One precursor B cell ALL sample was analyzed for R1 and R2 only. Expression levels of these receptors were heterogeneous, AML samples expressed more often TRAIL receptors R1 (P Ͻ 0.05) and R3 (P Ͻ 0.05) compared with ALL samples (Table 1 ). There were no significant differences in TRAIL receptor gene expression between precursor B and precursor T cell ALL (data not shown). Comparing TRAILsensitive and TRAIL-resistant cases, no correlation between the receptor expression levels and TRAIL susceptibility was observed for all cases examined (Table 1) as well as comparing TRAIL-sensitive and TRAIL-resistant cases within leukemia subtypes (data not shown). Figure 3 shows representative examples of TRAIL receptor analysis by RT-PCR as described in Materials and methods.
TRAIL susceptibility in the context of constitutive NF-B activation status of acute leukemia cells
Thirty-nine arbitrarily chosen cell samples with different levels of TRAIL susceptibility were examined for their constitutive NF-B activation status by electrophoretic mobility shift assay. Figure 4a shows representative examples of NF-B DNA binding activity in cell samples from patients with AML and ALL. NF-B activity in individual cell samples was assumed if a NF-B shift in the EMSA was observed. Results were standardized against Oct-1 shift activity as an internal control for each sample. Constitutive NF-B appears to be a common characteristic not only of ALLs, as reported previously, 38 but was also observed in cell samples from patients with AML (Table 1) . Interestingly, in this series, precursor B cell ALL (18 of 20) and AML (eight of nine) disclosed more often a constitutive NF-B activity as compared to precursor T cell ALL (four of 10) samples (P Ͻ 0.01 and P Ͻ 0.05, respectively). However, no significant correlation between TRAIL sensitivity and NF-B shift activity was observed, either for all cases examined (Table 1) or within the leukemia subtypes (data not shown).
Figure 2
Flow cytometric detection of spontaneous apoptosis in vitro, doxorubicin-induced apoptosis and TRAIL-induced cell death by annexinV-staining. (% values = viable, annexinV and propidium iodide negative cells in the lower left quadrant. Note the autofluorescence of the chemotherapeutic agent doxorubicin.) (a) Incubation for 24 h at 37°C in standard RPMI medium alone; (b) coincubation for 24 h at 37°C with TRAIL (1 g/ml); (c) coincubation for 24 h at 37°C with doxorubicin (2.5 g/ml); (d) coincubation for 24 h at 37°C with doxorubicin (2.5 g/ml) and TRAIL (1 g/ml). Table 1 Relative TRAIL receptor gene expression and constitutive NF-B activation status analysis in acute leukemia subtypes and in TRAILsensitive (у10% TRAIL sensitive cells/sample) and TRAIL-resistant (Ͻ10% TRAIL sensitive cells/sample) acute leukemia cell samples by semiquantitative RT-PCR and EMSA as described in Materials and methods (23) 1 (11) 8 (27) 3 (25) 6 (22) TRAIL receptors: л, no expression; +, weak expression; ++, strong expression, as defined in Materials and methods. NF-B DNA binding activity consisted of p50/p50 homodimers and p50/p65 heterodimers as determined by supershift analysis using antibodies directed against these proteins (Figure 4b) .
Overall
Influence of the chemotherapeutic agent doxorubicin on TRAIL susceptibility of acute leukemic cells
To determine whether cytotoxic drugs modulate TRAIL susceptibility, 49 consecutive acute leukemic cell samples (21 AML, 19 precursor B cell ALL, nine precursor T cell ALL) were coincubated with doxorubicin in vitro as described in Materials and methods. This agent sensitized four of 35 initially TRAIL-resistant samples (one AML, patient No. 25560; three precursor B cell ALL, patient Nos 24048, 25851, 25869) to TRAIL-induced apoptosis (у10% specific TRAIL-induced apoptotic cells/sample) ( Table 2 and as an example Figure 2) . Coincubation with doxorubicin augmented TRAIL-induced apoptosis (у10% additional specific TRAIL-induced apoptotic cells/sample) in two of 14 initially TRAIL-sensitive samples (two precursor B cell ALL, patient Nos 25229, 28474) ( Table 2) . In these cases, this sensitization/augmentation effect was seen for the 2.5 g/ml and 12.5 g/ml doxorubicin concentrations. We did not observe this effect at a lower (0.5 g/ml) concentration, most probably due to the rather low apoptosis-inducing effect of this doxorubicin concentration.
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Figure 4
Examples for NF-B activation status analysis in leukemic cell samples by electrophoretic mobility shift assay (EMSA). (a) NF-B (upper panel) and Oct-1 (lower panel) DNA binding activity from 10 representative leukemic cell samples are shown. The two left lanes represent two Hodgkin's disease cell lines (L428 and L1236, respectively) with known high constitutive NF-B DNA binding activity as positive controls. (b) Supershift analysis in three representative leukemic samples used in (a) was done with antibodies directed against the NF-B subunits p50 (clone H119, Santa Cruz, CA, USA) and p65 (Upstate Biotech, Lake Placid, NY, USA). Whole cell extracts were assayed for NF-B and Oct-1 DNA binding activity (upper and lower panels, respectively). The free DNA is not shown. The migration of all protein/DNA complexes are indicated (ns, non-specific).
Discussion
In this study, we examined 129 cell samples of patients with de novo acute leukemia for their constitutive in vitro susceptibility to TRAIL-induced apoptosis. We correlated these findings with TRAIL receptor mRNA expression levels and NF-B activation status of the investigated cases. Moreover, the influence of the cytotoxic drug doxorubicin on the in vitro TRAIL susceptibility of acute leukemic cells was investigated.
Recently, Clodi et al 17 reported 11 (38%) of 29 precursor B cell ALL samples with at least 10% TRAIL-sensitive cells/sample. Comparatively, 27% (11/41) of the precursor B cell ALL samples examined in our study fulfilled this criteria. Despite the rather low number of TRAIL sensitive leukemic cell samples in this subtype, we found that precursor B cell ALL disclosed a higher in vitro susceptibility to TRAIL-induced apoptosis compared with AML and precursor T cell ALL. This is in contrast to the constitutive susceptibility to CD95(Fas/Apo-1)-induced apoptosis of leukemic cells: precursor B cell ALL cells were significantly less CD95-sensitive compared with precursor T cell ALL and AML cells 34, 35, 39 Compared with our previous studies on CD95-induced apoptosis in AML and precursor T cell ALL, these subtypes seem to be less sensitive to TRAIL-than to CD95-induced apoptosis. In contrast, precursor B cell ALL samples were rather more susceptible to TRAIL-than to CD95-induced apoptosis. 34, 35, 39 The independence of CD95 and TRAIL susceptibility is well documented in normal T cells as well as in individual leukemic cell samples. 18, 40 To determine whether the expression pattern of TRAIL receptors R1-R4 might explain the rather low TRAIL susceptibility observed, we examined constitutive mRNA levels of these receptors by semi-quantitative RT-PCR. Relative expression levels were heterogeneous, and neither the expression of the signal-transducing TRAIL receptors R1 and R2 nor of the decoy receptors R3 and R4 correlated with TRAIL susceptibility. Thus, our findings suggest that the expression pattern of TRAIL receptors R1-R4 does not determine TRAIL susceptibility of leukemic cells. This is in line with several studies, which also found no correlation between TRAIL susceptibility and TRAIL receptor expression levels in normal and malignant cell types. 12, 17, 28, [41] [42] [43] Our observation that most of the leukemic cell samples examined expressed mRNA of the TRAIL receptors R1 and R2 indicates that downstream intracellular checkpoints might regulate the TRAIL susceptibility of primary leukemic cells. It was recently shown that TRAIL induces apoptosis via the FADD/caspase-8 signaling pathway in a Bcl-2 and Bcl-xL-independent manner and that caspase-8 deficiency completely abrogated TRAIL sensitivity. [44] [45] [46] Caspase-8-dependent cleavage of Bid and consecutive Bax activation may also connect TRAIL-induced cell death to the mitochondrial apoptosis pathway. 47, 48 Further studies on TRAIL-induced cell death in primary acute leukemia should focus on intracellular molecules regulating TRAILmediated cell death.
The NF-B family of transcription factors has important regulatory functions for both normal and malignant hematopoiesis. 49, 50 NF-B suppresses apoptosis and mounts a protective response against anthracyclines and topoisomerase-II inhibitors. [51] [52] [53] Inhibition of TRAIL-induced NF-B activation augmented apoptosis induction by TRAIL and attenuated apoptosis resistance in leukemia cell lines as well as five of six primary leukemic cell samples examined. 54 In our previous study, 39 (93%) of 42 ALL samples had an activated NF-B status. 38 Thus, it is intriguing to speculate that a high constitutive NF-B activity provides a negative regulatory signal in TRAIL-mediated apoptosis and might explain the generally low TRAIL susceptibility observed in our study. We therefore examined whether NF-B activation status differs between TRAIL-sensitive and TRAIL-resistant cases. In accordance with our previous study, 38 leukemic cell samples in this series generally showed a high constitutive NF-B activation status. In this study, however, NF-B activity was markedly lower in precursor T cell ALL compared with other leukemia subtypes. Given the low number of patients examined, this effect should be interpreted with caution, and its statistical significance in a larger series of ALL samples is under our current investigation. However, we could not detect any significant differences in the NF-B activation status between TRAIL-sensitive and TRAIL-resistant cell samples. These data suggest that constitutive NF-B activity does not determine resistance to TRAILinduced apoptosis in leukemic cells. However, future studies should further investigate whether an attenuation of the constitutive high NF-B activity either by pharmacological agents or by the expression of a NF-B superrepressor 55 enhance TRAIL-induced apoptosis in leukemic cells. Cytotoxic drugs like doxorubicin induce and enhance TRAIL susceptibility in tumor cells in vitro and in vivo. [9] [10] [11] In our study, the apoptosis-inducing effect of TRAIL on leukemic blasts could be enhanced in a certain number of cases by coincubation with doxorubicin. Interestingly, a recent study showed that a sequential treatment of the acute leukemia cell line HL60 with anticancer drugs followed by TRAIL induced significantly more apoptosis than coincubation of TRAIL with chemotherapeutic drugs. 28 We therefore cannot rule out that the observed TRAIL sensitization in our study could be markedly enhanced by the above-described sequential treatment of the leukemic cells. Our findings support the assumption that TRAIL-mediated apoptosis could amplify the response to cytotoxic drugs in tumor cells. 1 Further studies on TRAIL toxicity on normal human cells will show whether TRAIL has the potential as a cotherapeutic in cancer therapy or whether it will share the fate of TNF␣ and CD95L which cannot be used in systemic anticancer therapy because of severe toxic side-effects. 1 To our knowledge, this series is so far the largest study on the in vitro TRAIL susceptibility of primary acute leukemia cells. However, due to the rather low frequency of TRAILsusceptible leukemic cell samples observed, further studies of immunologically and cytogenetically defined prognostic subgroups are necessary to reveal possible clinically relevant differences in the sensitivity to TRAIL-induced apoptosis in acute leukemia. We conclude that constitutive TRAIL susceptibility differs between leukemia subtypes and does not correlate with mRNA expression levels of the TRAIL receptors R1-R4 as well as constitutive NF-B activation status. Therefore, future studies have to focus on possible intracellular checkpoints regulating TRAIL-induced cell death. The observed sensitization of leukemic cells to TRAIL by doxorubicin in vitro indicates that TRAIL should be further evaluated as to its possible role as an in vivo cotherapeutic in acute leukemia.
